{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:14:00Z","timestamp":1793812440740,"version":"4.6.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["NIH grant R01AG081466"],"award-info":[{"award-number":["NIH grant R01AG081466"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["NIH grant P30AG024827"],"award-info":[{"award-number":["NIH grant P30AG024827"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00198-025-07717-5","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:36:39Z","timestamp":1760700999000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A systematic review and meta-analysis of sequential treatment strategies for osteoporosis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-4696","authenticated-orcid":false,"given":"Smita","family":"Nayak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Greenspan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"7717_CR1","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520\u20132526","journal-title":"J Bone Miner Res"},{"key":"7717_CR2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1359\/jbmr.070315","volume":"22","author":"ND Nguyen","year":"2007","unstructured":"Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22:781\u2013788","journal-title":"J Bone Miner Res"},{"key":"7717_CR3","doi-asserted-by":"crossref","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy\u00a0(2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785\u2013795","DOI":"10.1001\/jama.285.6.785"},{"key":"7717_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 22:465\u2013475","journal-title":"J Bone Miner Res"},{"key":"7717_CR5","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00198-010-1419-7","volume":"22","author":"SW Blume","year":"2011","unstructured":"Blume SW, Curtis JR (2011) Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int 22:1835\u20131844","journal-title":"Osteoporos Int"},{"key":"7717_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/1060028020970518","volume":"55","author":"SA Williams","year":"2021","unstructured":"Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR (2021) Economic burden of osteoporosis-related fractures in the US Medicare population. Ann Pharmacother 55:821\u2013829","journal-title":"Ann Pharmacother"},{"key":"7717_CR7","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00198-010-1480-2","volume":"22","author":"S Morin","year":"2011","unstructured":"Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD (2011) Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int 22:2439\u20132448","journal-title":"Osteoporos Int"},{"key":"7717_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326","journal-title":"J Bone Miner Res"},{"key":"7717_CR9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102","journal-title":"Osteoporos Int"},{"key":"7717_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"key":"7717_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1\u201346","journal-title":"Endocr Pract"},{"key":"7717_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M19-0961","volume":"171","author":"A Siu","year":"2019","unstructured":"Siu A, Allore H, Brown D, Charles ST, Lohman M (2019) National institutes of health pathways to prevention workshop: research gaps for long-term drug therapies for osteoporotic fracture prevention. Ann Intern Med 171:51\u201357","journal-title":"Ann Intern Med"},{"key":"7717_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"7717_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"7717_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC et al (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"7717_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"7717_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","volume":"19","author":"S Adami","year":"2008","unstructured":"Adami S, San Martin J, Mu\u00f1oz-Torres M et al (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1\u201334)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87\u201394","journal-title":"Osteoporos Int"},{"key":"7717_CR18","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","volume":"26","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P (2015) Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int 26:2521\u20132527","journal-title":"Osteoporos Int"},{"key":"7717_CR19","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","volume":"64","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P (2015) Denosumab in treatment-naive and pre-treated with zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers. Metabolism 64:1291\u20131297","journal-title":"Metabolism"},{"key":"7717_CR20","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res 34:2220\u20132228","journal-title":"J Bone Miner Res"},{"key":"7717_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jocd.2021.01.006","volume":"24","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Trovas G, Yavropoulou MP, Tournis S (2021) Efficacy of antiosteoporotic medications in patients with rebound-associated fractures after denosumab discontinuation. J Clin Densitom 24:591\u2013596","journal-title":"J Clin Densitom"},{"key":"7717_CR22","first-page":"S377","volume":"32","author":"JP Bilezikian","year":"2017","unstructured":"Bilezikian JP, Fitzpatrick LA, Williams GC, Hu MY, Hattersley G, Rizzoli R (2017) Bone mineral density and bone turnover marker changes with sequential abaloparatide\/alendronate: results of ACTIVExtend. J Bone Miner Res 32:S377","journal-title":"J Bone Miner Res"},{"key":"7717_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"7717_CR24","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949\u20132957","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR25","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852\u2013860","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR26","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00198-018-4434-8","volume":"29","author":"D Burkard","year":"2018","unstructured":"Burkard D, Beckett T, Kourtjian E, Messingschlager C, Sipahi R, Padley M, Stubbart J (2018) Effects of bone remodeling agents following teriparatide treatment. Osteoporos Int 29:1351\u20131357","journal-title":"Osteoporos Int"},{"key":"7717_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00198-007-0475-0","volume":"19","author":"F Cosman","year":"2008","unstructured":"Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R (2008) Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19:529\u2013535","journal-title":"Osteoporos Int"},{"key":"7717_CR28","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772\u20133780","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR29","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"7717_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","volume":"92","author":"F Cosman","year":"2017","unstructured":"Cosman F, Miller PD, Williams GC et al (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc 92:200\u2013210","journal-title":"Mayo Clin Proc"},{"key":"7717_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to Denosumab. J Bone Miner Res 33:1219\u20131226","journal-title":"J Bone Miner Res"},{"key":"7717_CR32","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/jbmr\/zjae116","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Oates M, Betah D, Timoshanko J, Wang Z, Ferrari S, McClung MR (2024) Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Miner Res 39:1268\u20131277","journal-title":"J Bone Miner Res"},{"key":"7717_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12020-023-03431-6","volume":"82","author":"G Dito","year":"2023","unstructured":"Dito G, Lugaresi M, Degradi C, Guabello G, Longhi M, Corbetta S (2023) Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study. Endocrine 82:181\u2013189","journal-title":"Endocrine"},{"key":"7717_CR34","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F et al (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European study of Forsteo (EUROFORS). J Bone Miner Res 24:726\u2013736","journal-title":"J Bone Miner Res"},{"key":"7717_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00774-015-0731-x","volume":"35","author":"K Ebina","year":"2017","unstructured":"Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T, Tsukamoto Y, Yoshikawa H (2017) The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab 35:91\u201398","journal-title":"J Bone Miner Metab"},{"key":"7717_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88:105219","journal-title":"Joint Bone Spine"},{"key":"7717_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","volume":"31","author":"K Ebina","year":"2021","unstructured":"Ebina K, Hashimoto J, Kashii M et al (2021) Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Mod Rheumatol 31:485\u2013492","journal-title":"Mod Rheumatol"},{"key":"7717_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"7717_CR39","doi-asserted-by":"publisher","first-page":"753185","DOI":"10.3389\/fendo.2021.753185","volume":"12","author":"Y Hirooka","year":"2021","unstructured":"Hirooka Y, Nozaki Y, Okuda S, Sugiyama M, Kinoshita K, Funauchi M, Matsumura I (2021) Four-year teriparatide followed by denosumab vs. continuous denosumab in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Frontiers in endocrinology 12:753185","journal-title":"Frontiers in endocrinology"},{"key":"7717_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00223-022-00962-4","volume":"111","author":"N Hong","year":"2022","unstructured":"Hong N, Shin S, Lee S, Kim KJ, Rhee Y (2022) Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis. Calcif Tissue Int 111:47\u201355","journal-title":"Calcif Tissue Int"},{"key":"7717_CR41","doi-asserted-by":"publisher","first-page":"A256","DOI":"10.1210\/jendso\/bvad114.473","volume":"7","author":"N Hong","year":"2023","unstructured":"Hong N, Shin S, Kim H, Rhee Y (2023) Romosozumab after denosumab improves lumbar spine bone mineral density and microarchitecture greater than denosumab continuation in postmenopausal women. J Endocr Soc 7:A256","journal-title":"J Endocr Soc"},{"key":"7717_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"7717_CR43","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30:2437\u20132448","journal-title":"Osteoporos Int"},{"key":"7717_CR44","first-page":"1466","volume":"28","author":"YI Kim","year":"2021","unstructured":"Kim YI, Kim SW, Han SJ, Suh CS, Ku SY, Kim H (2021) Efficacy of sequential treatment with bisphosphonate compared to prolonged denosumab treatment after discontinuation of denosumab in postmenopausal osteoporosis. Menopause 28:1466","journal-title":"Menopause"},{"key":"7717_CR45","doi-asserted-by":"publisher","first-page":"116480","DOI":"10.1016\/j.bone.2022.116480","volume":"162","author":"T Kobayakawa","year":"2022","unstructured":"Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y (2022) Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: the prospective VICTOR study. Bone 162:116480","journal-title":"Bone"},{"key":"7717_CR46","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","volume":"15","author":"ES Kurland","year":"2004","unstructured":"Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1\u201334)]. Osteoporos Int 15:992\u2013997","journal-title":"Osteoporos Int"},{"key":"7717_CR47","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet (london, england) 390:1585\u20131594","journal-title":"Lancet (london, england)"},{"key":"7717_CR48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155","journal-title":"Lancet"},{"key":"7717_CR49","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34:419\u2013428","journal-title":"J Bone Miner Res"},{"key":"7717_CR50","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1210\/jc.2019-00924","volume":"104","author":"H Lyu","year":"2019","unstructured":"Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, Leder BZ, Solomon DH (2019) Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use. J Clin Endocrinol Metab 104:5611\u20135620","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","volume":"41","author":"M McClung","year":"2007","unstructured":"McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122\u2013128","journal-title":"Bone"},{"key":"7717_CR52","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397\u20131406","journal-title":"J Bone Miner Res"},{"key":"7717_CR53","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","volume":"31","author":"MR McClung","year":"2020","unstructured":"McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int 31:2231\u20132241","journal-title":"Osteoporos Int"},{"key":"7717_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10512","author":"MR McClung","year":"2021","unstructured":"McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Shi Y, Timoshanko J, Libanati C, Chines A, Oates MK (2021) Skeletal responses to romosozumab after 12 months of denosumab. JBMR Plus. https:\/\/doi.org\/10.1002\/jbm4.10512","journal-title":"JBMR Plus"},{"key":"7717_CR55","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785\u20133793","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR56","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR57","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1185\/03007990802466595","volume":"24","author":"H Minne","year":"2008","unstructured":"Minne H, Audran M, Sim\u00f5es ME, Obermayer-Pietsch B, Sigurdsson G, Mar\u00edn F, Dalsky GP, Nickelsen T (2008) Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 24:3117\u20133128","journal-title":"Curr Med Res Opin"},{"key":"7717_CR58","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00198-022-06570-0","volume":"34","author":"S Mori","year":"2023","unstructured":"Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S (2023) Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 34:189\u2013199","journal-title":"Osteoporos Int"},{"key":"7717_CR59","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/jbmr.2216","volume":"29","author":"C Muschitz","year":"2014","unstructured":"Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H (2014) Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density\u2013the CONFORS study. J Bone Miner Res 29:1777\u20131785","journal-title":"J Bone Miner Res"},{"key":"7717_CR60","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/jbm4.10054","volume":"2","author":"R Niimi","year":"2018","unstructured":"Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2018) Efficacy of switching from Teriparatide to bisphosphonate or Denosumab: a prospective, randomized, open-label trial. JBMR Plus 2:289\u2013294","journal-title":"JBMR Plus"},{"key":"7717_CR61","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291\u20131299","journal-title":"Obstet Gynecol"},{"key":"7717_CR62","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129\u20132134","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR63","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"7717_CR64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jos.2016.11.022","volume":"22","author":"F Yoshiki","year":"2017","unstructured":"Yoshiki F, Nishikawa A, Taketsuna M, Kajimoto K, Enomoto H (2017) Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: post hoc analysis of a prospective observational study. J Orthop Sci 22:330\u2013338","journal-title":"J Orthop Sci"},{"key":"7717_CR65","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS Solling","year":"2020","unstructured":"Solling AS, Harslof T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35:1858\u20131870","journal-title":"J Bone Miner Res"},{"key":"7717_CR66","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155\u2013e4162","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR67","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR68","doi-asserted-by":"publisher","first-page":"e5496","DOI":"10.1097\/MD.0000000000005496","volume":"95","author":"S Lou","year":"2016","unstructured":"Lou S, Lv H, Wang G, Li Z, Li M, Zhang L, Tang P (2016) The effect of sequential therapy for postmenopausal women with osteoporosis: a PRISMA-compliant meta-analysis of randomized controlled trials. Medicine (Baltimore) 95:e5496","journal-title":"Medicine (Baltimore)"},{"key":"7717_CR69","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","volume":"30","author":"F Cosman","year":"2024","unstructured":"Cosman F, Langdahl B, Leder BZ (2024) Treatment sequence for osteoporosis. Endocr Pract 30:490\u2013496","journal-title":"Endocr Pract"},{"key":"7717_CR70","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1210\/clinem\/dgad496","volume":"109","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK, Leder BZ (2024) Sequential therapy for the long-term treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 109:303\u2013311","journal-title":"J Clin Endocrinol Metab"},{"key":"7717_CR71","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY et al (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632\u2013642","journal-title":"J Bone Miner Res"}],"updated-by":[{"DOI":"10.1007\/s00198-025-07751-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07717-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07717-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07717-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:02:50Z","timestamp":1769515370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07717-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7717"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07717-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is a a consistent misspelling of the term \u201cromosozumab\u201d (letters \u201cs\u201d and \u201cz\u201d transposed.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Please update the incorrect word \"romozosumab\" with the correct version \"Romosozumab\" throughout the article.","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":11,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":12,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00198-025-07751-3","URL":"https:\/\/doi.org\/10.1007\/s00198-025-07751-3","order":14,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}